問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



China Medical University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,076

    Total Beds

  • 884

    Total Doctors

  • ctcadm.cmuh@gmail.com
  • Clinical Trial Center
  • 04-22052121#1471~1485
  • 404Taichung CityTaichung NorthNo. 2, Yude Rd., North Dist., Taichung City 404332, Taiwan (R.O.C.)

Recruiting Trial

693Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1743Cases

2026-07-01 - 2029-05-31

Phase III

Not yet recruiting
A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    注射用凍晶粉末 膜衣錠 靜脈點滴注射劑

Participate Sites
7Sites

Not yet recruiting1Sites

2025-08-01 - 2027-04-09

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-08-01 - 2030-04-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2025-08-01 - 2025-09-09

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Terminated2Sites

2025-10-01 - 2030-12-24

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-10-01 - 2028-04-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-10-15 - 2028-10-31

Phase II

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-07-01 - 2029-12-30

Phase III

Not yet recruiting
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)

  • Condition/Disease

    Weight Management

  • Test Drug

    膜衣錠

Participate Sites
10Sites

Not yet recruiting10Sites

2026-08-01 - 2028-12-31

Phase III

Not yet recruiting
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)

  • Condition/Disease

    Obesity or Overweight

  • Test Drug

    注射液

Participate Sites
11Sites

Not yet recruiting1Sites

2025-11-03 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

1 23 24 25 26 27 175
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB